Polyendocrine Metabolic Ovarian Syndrome
nammu.academy · Women's Health & Medical Justice
They finally
changed
the name.
PCOS is now PMOS. Here's why that matters enormously — and why it took 14 years, 22,000 voices, and a condition affecting 170 million women to get here.
There's something particular about the moment you find out the condition you've been living with — or watching someone you love live with — was named after a feature it doesn't even reliably have. That the word your doctor used, the term on the leaflet, the diagnosis in the file, was not just incomplete. It was wrong. And it was wrong in a way that had consequences. Real, measurable, life-altering consequences.
This week, after 14 years of global collaboration and the voices of more than 22,000 patients and clinicians from every world region, that got corrected. On May 12, 2026, The Lancet published the results of an unprecedented consensus process. Polycystic ovary syndrome — PCOS — was officially renamed polyendocrine metabolic ovarian syndrome. PMOS.
I want to talk about why this matters. Not just as a terminological update — though that alone is significant. But because the name change is a window into something much bigger: the way that a single wrong word, repeated across decades of medical education and clinical practice, can quietly derail millions of women's access to accurate diagnosis, appropriate treatment, and basic understanding of their own bodies.
The cysts were never the point. They were never even reliably present. And yet there they were — right there in the name, setting the agenda, narrowing the frame, sending patients to gynaecologists when what they often needed was an endocrinologist and a metabolic workup. Sending women home reassured when what they needed was to be taken seriously.
"Renaming this condition is more than semantics. It's about finally recognising the full reality of what patients experience." — Dr Melanie Cree, University of Colorado
I'll be honest: when I first heard about the rename, my immediate reaction was something between relief and fury. Relief, because the science finally caught up with what so many women have been saying for years — that this condition is vastly bigger than its name suggested. Fury, because it took this long. Because 14 years is a lot of missed diagnoses. A lot of women told their hormonal acne was just stress, their irregular cycles just normal variation, their metabolic symptoms too subtle to warrant real investigation. A lot of women who got a PCOS diagnosis and then got very little else besides a pill and a pamphlet about weight loss.
So let's go through it properly. Let's talk about what PMOS actually is, why the old name was doing so much damage, and what — if anything — changes now for the one in eight women living with it.
What was wrong
with the old name
The term "polycystic ovary syndrome" was coined in 1935 — based on the observation that some women with this constellation of symptoms had enlarged ovaries containing multiple follicles that looked, on early imaging, like cysts. The name stuck. Decades passed. Imaging improved. Understanding deepened. And the science gradually revealed that those "cysts" weren't actually cysts — they were immature follicles, and they weren't even present in all women with the condition. Up to a third of women with PCOS didn't have polycystic ovarian morphology at all. And crucially, polycystic ovaries could appear in women who didn't have the syndrome.[1]
So the name was, from its foundation, built on a feature that was neither universal nor specific. But the problem wasn't just anatomical inaccuracy. It was what the name implied about what kind of condition this was — and therefore, who should be treating it, how it should be studied, and what patients should expect to be told.
A name with "ovary" at the centre frames this as a gynaecological condition. Send it to obs and gynae. Manage it reproductively. Focus on fertility. Move on. What the name completely obscured was the endocrine and metabolic reality: the fact that this condition involves multiple interacting hormonal disturbances — insulin, androgens, neuroendocrine hormones — that have consequences far beyond the ovaries.[2]
What the name obscured — the full metabolic picture
PMOS involves three primary pathological mechanisms: hyperandrogenism (elevated androgens from both ovarian and adrenal sources), disordered ovulation, and — most significantly and most consistently — insulin resistance with compensatory hyperinsulinemia. That last feature is present in 85% of affected patients, including 75% of lean patients. Not just in women who are overweight. Not just a secondary consequence. A central, defining feature that was systematically underemphasised by a name that pointed everyone toward the ovaries.[2]
The metabolic consequences of sustained insulin resistance compound significantly over time: threefold increased risk of type 2 diabetes, elevated risk of cardiovascular disease, metabolic dysfunction-associated liver disease, and dyslipidaemia. Women with PMOS also have higher rates of depression, anxiety, sleep apnoea, and endometrial cancer. This is not a syndrome limited to irregular periods and fertility concerns. It is a lifelong, multisystem condition. The name was hiding that. For 91 years.[3]
Interactive — what the new name actually means
Tap each word to explore what it means.
The international consensus process that produced this name was, by any measure, extraordinary. Led by Professor Helena Teede at Monash University in Australia, it engaged 56 academic, clinical, and patient organisations across six continents. Over 22,000 people — doctors, researchers, patients, advocacy groups — shared their views across surveys conducted between 2017 and 2026. Three finalist names were put to global workshops. PMOS won in a landslide.[1]
The principles the process prioritised tell you everything about what was wrong with the old name: scientific accuracy, stigma avoidance, clarity, cultural appropriateness. The primary thing patients said they wanted from a new name was to avoid stigma. Because the old name had created stigma. "Polycystic" implied something visibly, structurally wrong with the ovaries. "Syndrome" with no metabolic or hormonal framing implied something vague, something lifestyle-adjacent, something that could be fixed with diet and the contraceptive pill and perhaps a bit more willpower.
That framing cost women. Measurably. Let's look at the numbers.
What PMOS actually
is
PMOS has a wide variety of signs and symptoms — which is part of why it has been so consistently underdiagnosed and so difficult for patients to navigate. There is no single definitive test. There is no one presentation. Two women with PMOS can look entirely different clinically, which has historically allowed individual symptoms to be dismissed in isolation rather than recognised as part of a connected pattern.
At its core, PMOS is a condition of disrupted endocrine signalling. The hypothalamic-pituitary-ovarian axis — the hormonal feedback loop that regulates the menstrual cycle — is dysregulated. This leads to elevated androgens, which produce symptoms including irregular or absent periods, acne, hirsutism (unwanted hair growth), and alopecia. It also leads to impaired ovulation, which affects fertility. And it is underpinned — in the vast majority of cases — by insulin resistance, which the condition shares with type 2 diabetes as a core pathological feature.[3]
The genetic architecture of PMOS, which large-scale genomic analyses have now confirmed, spans neuroendocrine, metabolic, and reproductive pathways simultaneously. It is polygenic in origin — meaning it arises from multiple genetic variants interacting with environmental factors, not from a single gene mutation. This helps explain why it presents so variably, and why it affects systems well beyond the reproductive tract.[2]
Interactive — the systems PMOS affects
Tap each system to expand.
The diagnostic criteria for PMOS require two of three features: irregular ovulation (typically evidenced by irregular or absent periods), hyperandrogenism (either clinical or biochemical), and polycystic ovarian morphology on ultrasound. You do not need all three. You do not need the ovarian morphology. The condition is still vastly more often framed in gynaecological terms than endocrine ones — a legacy of the old name that the new one is specifically designed to interrupt.
What this means in practice is that women with PMOS have often been managed around their most visible reproductive symptoms while the metabolic and psychological dimensions of their condition went unaddressed for years. The GP who prescribed the pill for irregular periods and moved on. The specialist who measured androgen levels but didn't check fasting insulin or metabolic markers. The system that treats a multisystem condition as a single-system problem, because the name told it to.
The name told the system where to look. And so the system looked there — and missed everything else that was happening.
How the name change happened — 14 years in the making
What changes now —
and what doesn't yet
I want to be honest about the limits of a name change, because I think the temptation after something like this — a hard-won, long-awaited correction — is to feel like the work is done. It isn't. A rename does not automatically translate into better diagnostic rates, more appropriate treatment, or more funding for research. It is a precondition for those things. It creates the language that makes them possible. But language alone does not move a system.
What the rename does immediately is reframe the conversation — in medical education, in clinical guidelines, in research funding applications, in the questions patients think to ask. When a condition is named after its endocrine and metabolic features, those features become impossible to ignore. The new name instructs the clinician to look at insulin, at cardiovascular risk, at the psychological dimension, not just at the ovaries. That instruction matters. It will take years to fully propagate through medical systems that were built around the old framing. But it starts now.
The consensus process also developed an 8-stage implementation roadmap: updates to international disease classification systems, clinical guideline revisions, medical education curricula, public awareness campaigns. The NHS has stated it will consider recommendations to adopt the new terminology. The Endocrine Society, one of 56 organisations involved in the process, is already moving. This is a real, coordinated transition — not just a symbolic one.[1]
What doesn't change: the lived experience of the 70% of people with PMOS who are still undiagnosed. The diagnostic delays that have accumulated over decades. The women who spent years being told their symptoms were stress, or lifestyle, or just how their body was — and who now have to navigate a healthcare system that is only beginning to update its understanding. The rename is the beginning of a correction. It is not the correction itself.
If you suspect you have PMOS — what the science says to ask for
Advocating for a complete workup
Ask specifically about metabolic markers. A PMOS workup should include fasting insulin and glucose, a lipid panel, and liver function tests — not just testosterone levels and a pelvic ultrasound. If you've been investigated for PCOS and only had the ovarian picture examined, it is entirely reasonable to return and ask for the metabolic piece.
Seek an endocrinologist, not only a gynaecologist. The new name is a deliberate instruction. PMOS is a multi-system endocrine condition. A gynaecologist may be the right starting point for reproductive symptoms — but an endocrinologist is better placed to evaluate and manage the hormonal and metabolic dimensions of the condition comprehensively.
Know the diagnostic criteria. You need two of three: irregular ovulation (irregular or absent periods), hyperandrogenism (clinical or biochemical — so either visible symptoms like acne and hirsutism, or elevated androgen levels on bloodwork), or polycystic ovarian morphology on ultrasound. You do not need the ultrasound finding. You do not need all three.
Don't let weight be the gatekeeping issue. Insulin resistance is present in 75% of lean patients with PMOS. The metabolic features of this condition are not contingent on BMI, and a clinician who dismisses metabolic investigation because of a patient's weight or weight because of a patient's BMI is working from outdated guidelines.
The psychological symptoms are part of the condition. Higher rates of depression, anxiety, and sleep disorders are documented features of PMOS — not just understandable responses to having it. If you are experiencing these symptoms alongside the hormonal and metabolic picture, they are clinically relevant and worth raising explicitly.
Lorna Berry, an Australian woman with PMOS who was part of the renaming process, said this: "This is about accountability and progress. It is about my daughters, their daughters, and the countless women yet to be born. We deserve clarity, understanding, and equitable healthcare from the very beginning."
I keep returning to that. The countless women yet to be born. Because that's the other thing a name change does — it changes what future generations of clinicians are taught, what future patients are told, what future research is funded to investigate. The correction begins to travel forward in time as well as backward through the files of the women who needed it earlier.
PCOS was always too small a name for what this condition actually is. PMOS isn't perfect — no name for something this complex could be. But it is honest. It says: this is hormonal, this is metabolic, this is systemic, this is real. And sometimes, that's where everything has to start.
With love and science, always —
nammu.academy
References
- Teede, H. J., et al. (2026). Polyendocrine metabolic ovarian syndrome, the new name for polycystic ovary syndrome: a multistep global consensus process. The Lancet. https://doi.org/10.1016/S0140-6736(26)00717-8
- Teede, H. J., Tay, C. T., Laven, J. J. E., Dokras, A., Moran, L. J., Piltonen, T. T., Costello, M. F., Boivin, J., Redman, L. M., Boyle, J. A., Norman, R. J., Mousa, A., & Joham, A. E. (2023). Recommendations from the 2023 international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Journal of Clinical Endocrinology & Metabolism, 108(10), 2447–2469. https://doi.org/10.1210/clinem/dgad463
- Cassar, S., Misso, M. L., Hopkins, W. G., Shaw, C. S., Teede, H. J., & Stepto, N. K. (2016). Insulin resistance in polycystic ovary syndrome: a systematic review and meta-analysis of euglycaemic-hyperinsulinaemic clamp studies. Human Reproduction, 31(11), 2619–2631. https://doi.org/10.1093/humrep/dew243
- Bozdag, G., Mumusoglu, S., Zengin, D., Karabulut, E., & Yildiz, B. O. (2016). The prevalence and phenotypic features of polycystic ovary syndrome: a systematic review and meta-analysis. Human Reproduction, 31(12), 2841–2855. https://doi.org/10.1093/humrep/dew218
- Cooney, L. G., & Dokras, A. (2017). Depression and anxiety in polycystic ovary syndrome: etiology and treatment. Current Psychiatry Reports, 19(11), 83. https://doi.org/10.1007/s11920-017-0834-2